RT Journal Article
SR Electronic
T1 Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: Randomized controlled trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.19.21257429
DO 10.1101/2021.05.19.21257429
A1 Elgohary, Mohamed Abdel-Salam
A1 Hasan, Eman Medhat
A1 Ibrahim, Amany Ahmad
A1 Ahmed Abdelsalam, Mohamed Farouk
A1 Abdel-Rahman, Raafat Zaher
A1 Zaki, Ashraf Ibrahim
A1 Elaatar, Mohamed Bakr
A1 Elnagar, Mohamed Thabet
A1 Emam, Mohamed Emam
A1 Hamada, Mahmoud Moustafa
A1 Abdel-Hamid, Taimour Mohamed
A1 Abdel-Hafez, Ahmad Samir
A1 Seadawy, Mohamed G.
A1 Fatoh, Ahmad Rashad
A1 Elsaied, Mohamed Ali
A1 Sakr, Marwa Abdel-Rahman
A1 Elkady, Ahmed Omar
A1 Shehata, Mohamed Muawad
A1 Nawar, Osama Mohamed
A1 Selem, Mohamed Abu-elnaga
A1 Abd-aal, Mohamed Saeed
A1 Lotfy, Hany Hafez
A1 Elnagdy, Tarek Refaat
A1 Helmy, Sherine
A1 Mubark, Magdy Amin
YR 2021
UL http://medrxiv.org/content/early/2021/05/21/2021.05.19.21257429.abstract
AB Background COVID-19 is a pandemic disease caused by SARS-CoV-2, which is an RNA virus similar to HCV in the replication process. Sofosbuvir/ledipasvir is an approved drug by the FDA to treat HCV infection. This study investigates the efficacy of Sofosbuvir/ledipasvir as a treatment for patients with moderate COVID-19 infection..Methods This is a single-blinded parallel-randomized controlled trial. The participants were randomized equally into the intervention group received Sofosbuvir/ledipasvir (S.L. group), and the control group received Oseltamivir, Hydroxychloroquine, and Azithromycin (OCH group). The primary outcomes were the cure rate over time and the incidence of serious adverse events. The secondary outcomes included the laboratory findings.Results Two hundred and fifty patients were divided equally into each group. Both groups were similar regarding gender, but age was higher in the S.L. group (p=0.001). In the S.L. group, 89 (71.2%) patients were cured, while only 51 (40.8%) patients were cured in the OCH group. The cure rate was significantly higher in the S.L. group (RR=1.75, p<0.001). Kaplan-Meir plot showed a considerably higher cure over time in the S.L. group (Log-rank test, p=0.032). There were no deaths in the S.L. group, but there were six deaths (4.8%) in the OCH group (RR=0.08, p=0.013). Seven patients (5.6%) in the S.L. group and six patients (4.8%) in the OCH group were admitted to ICU (RR=1.17, P=0.776). There was no significant difference between treatment groups regarding Total Leukocyte Count, Neutrophils count, Lymph and Urea.Conclusion Sofosbuvir/ledipasvir is suggestive of being effective in treating patients with moderate COVID-19 infection. Further studies are needed to compare Sofosbuvir/ledipasvir with the new treatment protocols.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04530422Funding StatementnoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical committee of Egyptian Centre for Research and Regenerative MedicineAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData Availability from the Corresponding Author